When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Rituximab - Wikipedia

   en.wikipedia.org/wiki/Rituximab

   Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...

3. Hypogammaglobulinemia - Wikipedia

   en.wikipedia.org/wiki/Hypogammaglobulinemia

   Protocols for different forms of primary immunodeficiency vary significantly. The aim of treatments implemented by specialist centers is usually to reduce the risk of complications. One method of treatment is by parenteral administration of gamma globulins, either monthly intravenously , subcutaneously , or more recently, by weekly self ...

4. Lymphocyte T-cell immunomodulator - Wikipedia

   en.wikipedia.org/wiki/Lymphocyte_T-Cell_Immuno...

   LTCI, manufactured by T-Cyte Therapeutics, has been conditionally approved by the United States Department of Agriculture (USDA) as an aid in the treatment of cats infected with feline leukemia virus (FeLV) and/or feline immunodeficiency virus (FIV), and the associated symptoms of lymphopenia, opportunistic infection, anemia, granulocytopenia ...

5. Immune-mediated thrombocytopaenia - Wikipedia

   en.wikipedia.org/wiki/Immune-mediated...

   Immune-mediated thrombocytopaenia (IMT) is a disease common in dogs and rare in cats. The disease is characterised by a low platelet count caused by destruction of the platelets from the immune system. IMT is the most common cause of thrombocytopaenia in dogs. [1]

6. Cancer immunotherapy - Wikipedia

   en.wikipedia.org/wiki/Cancer_immunotherapy

   Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.

7. Monoclonal antibody therapy - Wikipedia

   en.wikipedia.org/wiki/Monoclonal_antibody_therapy

   Since 2000, the therapeutic market for monoclonal antibodies has grown exponentially. In 2006, the "big 5" therapeutic antibodies on the market were bevacizumab, trastuzumab (both oncology), adalimumab, infliximab (both autoimmune and inflammatory disorders, 'AIID') and rituximab (oncology and